Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts

Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts

We aimed to evaluate the preclinical efficacy of GC1118, a novel anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), against glioblastoma (GBM) tumors using patient-derived xenograft (PDX) models. A total of 15 distinct GBM PDX models were used to evaluate the therapeutic efficac...

Full description

Bibliographic Details
Main Authors: Kyoungmin Lee, Harim Koo, Yejin Kim, Donggeon Kim, Eunju Son, Heekyoung Yang, Yangmi Lim, Minkyu Hur, Hye Won Lee, Seung Won Choi, Do-Hyun Nam
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
glioblastoma
epidermal growth factor receptor
monoclonal
xenograft
amplification
Online Access:https://www.mdpi.com/2072-6694/12/11/3210

Internet

https://www.mdpi.com/2072-6694/12/11/3210

Similar Items